Melamine

Quick links to important sections

Melamine

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melamine

Quick Facts

Property Description
Active ingredient Mepyramine maleate (Pyrilamine)
Form Oral preparations (tablet), Topical preparations (cream)
Pharmacological class First-generation antihistamine, H1 receptor antagonist
General purpose Relief from allergic conditions and pruritic skin disorders
Origin Synthetic organic compound

What Type of Medicine is Mepyramine?

In a pharmaceutical context, the substance often associated with this profile is the active compound Mepyramine, which is chemically synonymous with Pyrilamine. Mepyramine is classified as a first-generation antihistamine, belonging to the substituted ethylenediamine chemical group and functioning as an H1 receptor antagonist. This compound is a synthetic organic compound designed to counteract the effects of histamine, a substance central to the body's allergic conditions. The classification as a first-generation agent is a key differentiating factor, highlighting a structure that allows it to cross the blood-brain barrier (BBB), resulting in Central Nervous System (CNS) depressant properties and often causing sedation.

Composition, Forms, and General Purpose

The active component in pharmaceutical preparations is typically the salt form, Mepyramine maleate, formulated for either localized or systemic delivery. This ingredient is available in diverse pharmaceutical preparations, including oral preparations such as a tablet for systemic use and topical preparations such as a cream for dermal application. The compound is used to manage symptoms in patients suffering from hypersensitivity reactions and pruritic skin disorders (itching). Antihistamines like Mepyramine work by inhibiting the body's response to histamine. Therefore, this compound helps to ease discomfort by blocking the signals that lead to intense itching and swelling. The preparation's purpose is to provide relief by acting as an H1-blocking agent, mitigating the symptoms of irritation and localized swelling caused by allergic stimuli.

Regulatory References

  1. Pyrilamine (Mepyramine)
  2. Antihistamines: Mechanism of Action (NIH)

What side effects are possible with Melamine?

Possible Side Effects and Safety Information

Mepyramine maleate (Pyrilamine) is a first-generation antihistamine, and its official safety profile is defined by its effects on the Central Nervous System (CNS) and its potential for localized reactions. The terminology used is consistent with regulatory classifications.

Classification Details
Common Side Effects Drowsiness (somnolence) and sedation are the most frequent effects reported with systemic exposure. Other common effects include dizziness and headache.
System-Organ Classes Adverse reactions involve the Nervous System (e.g., confusion, excitement, tremor), Gastrointestinal Disorders (e.g., constipation, nausea), and Skin and Subcutaneous Tissue (e.g., sensitisation).
Topical Safety Notes For the cream formulation, local hypersensitivity reactions and skin sensitisation are documented. Systemic effects like drowsiness have been reported after application to large or broken skin areas. Repeated application for periods longer than a few days is not recommended.
Serious Adverse Reactions While rare, serious adverse events documented in regulatory sources include convulsions (seizures), hyperpyrexia, coma, and cardiorespiratory collapse, typically associated with overdose or overexposure.

Population-Specific Safety Considerations

Official labeling includes explicit warnings for specific patient groups:

  • Pediatric Population: Children may exhibit CNS stimulation (agitation, excitement) rather than depression, and are at high risk for serious adverse events following overdose. The topical form is contraindicated in premature infants and neonates.
  • Older Adults: This group may be more sensitive to systemic effects such as dizziness, drowsiness, and confusion, which increases the potential for falls.
  • Concomitant CNS Depressants: Combined use with other CNS depressants, including alcohol, significantly increases the risk and severity of CNS depression.

This regulatory profile establishes drowsiness as the most common effect while simultaneously outlining specific serious adverse events and population risks to guide safe use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with this compound is officially classified by regulatory authorities as a potentially life-threatening event, demanding immediate action. The chief clinical manifestations documented in official labeling primarily involve severe Central Nervous System (CNS) effects.

Documented Overdose Manifestations

The officially described presentation of overdosage includes unconsciousness as the primary sign, with convulsions occurring in the intervening periods. A severe overdose carries the risk of complications such as increased respiratory depression and the secondary risk of pneumonia.

Required Emergency Actions

It is mandated in official regulatory documents that you must seek immediate medical attention and contact a Poison Control Center right away in the event of any accidental overdose. This action is deemed critical for both adults and children, even if there are no immediate signs or symptoms of overdosage visible.

Population Risk and Management

Young children are explicitly identified in regulatory documents as being at risk for a dangerous or life-threatening outcome from accidental ingestion of significant amounts. The management procedures described are symptomatic and supportive, detailing specific interventions such as gastric lavage (stomach washout), the use of Parenteral Diazepam if convulsions occur, and the potential need for artificial respiration or oxygen. Procedural constraints require avoiding sedatives liable to increase respiratory depression.

Therapeutic Uses of Melamine

Mepyramine, generally known as Pyrilamine, is commonly used to provide short-term symptomatic assistance across clinical domains involving allergic and irritative states. It provides support that helps ease the overall symptom burden when acute manifestations interfere with daily comfort. The compound is also applied for the symptomatic relief of hay fever and upper respiratory allergies.

Core Therapeutic Focus

This medication is applied in clinical settings that involve acute or unstable symptom patterns characteristic of seasonal or perennial allergies, and it helps address symptom clusters that may become intense or disruptive. It is applicable within clinical settings that involve allergic rhinitis, pruritus (itching), hives (urticaria), and related manifestations. It is commonly used to help with symptoms that create noticeable physiological strain such as frequent sneezing, bothersome runny nose, and irritating nasal or ocular itching.

Supportive Benefit and Symptom Mitigation

Mepyramine is also relevant for easing symptoms related to inflammatory or irritative states of the skin, such as intense itching associated with allergic skin reactions. It contributes to easing the overall symptom load during symptomatic periods and supports the patient during difficult episodes. This agent plays a role in managing symptoms that indirectly interfere with daily functioning, particularly those that disrupt sleep.

Quick Fact: Relief for Pruritic and Allergic Distress
Symptom Category: Acute allergic and irritative manifestations
Common Use: Supports the management of sneezing, runny nose, and skin itching
Primary Benefit: Assists with maintaining a sense of stability when symptoms are more noticeable

Regulatory References

  1. NIH DailyMed service

Eligibility and Restrictions for Use

Eligibility for Melamine (Pyrilamine Maleate) Use

Official regulatory documents define specific populations who can and cannot use Pyrilamine maleate. Use is generally established for adults and adolescents (12 years of age and older) under standard labeled conditions. Use in children 6 to under 12 years of age is permitted but requires adherence to restricted quantities.

Contraindicated and Restricted Populations

Population Group Regulatory Status
Hypersensitivity or MAOI Use Absolutely Contraindicated (Must not use)
Children under 6 years Use Restricted (Requires mandatory medical consultation)
Pregnant/Breastfeeding Patients Use Restricted (Mandatory medical consultation)
Older Adults (Geriatric) Use with Caution (Increased sensitivity to effects)

Pyrilamine maleate is absolutely contraindicated for patients with a known allergy to the substance or for those currently taking or recently having discontinued a Monoamine Oxidase Inhibitor (MAOI).

Regulatory labeling also mandates that a doctor must be consulted prior to use by patients with certain pre-existing conditions, including glaucoma, difficulty in urination (due to prostatic issues), heart disease, high blood pressure, or respiratory issues like emphysema.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mepyramine (Pyrilamine) interaction information, as described in official regulatory labeling, is dominated by pharmacodynamic reinforcement and restrictions on concomitant CNS-acting substances.

Interaction Type Interacting Agents / Classes Official Outcome Classification
Formal Contraindication Thalidomide Increased risk of profound sedation
Pharmacodynamic Additive Effects CNS Depressants (e.g., Opioids, Antipsychotics, Anti-anxiety Agents, other Antihistamines, Hypnotics); Alcohol; Anticholinergic Drugs Additive CNS depression; Additive anticholinergic adverse effects
Metabolic Alteration Risk CYP2D6 Inhibitors/Inducers; CYP3A4 Inhibitors Potential for altered exposure or metabolism of Mepyramine or co-administered drugs
Cardiovascular Risk QTc Prolonging Drugs (e.g., Amiodarone, Arsenic trioxide) Increased risk or severity of QTc prolongation

The official labeling notes that co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants may increase the effect of the antihistamine component. Regarding non-medicinal substances, the regulatory text advises against co-use with Alcohol due to enhanced CNS depressant effects. Furthermore, the intake of Caffeine-Containing Products (foods, beverages, or medications) should be limited to mitigate documented CNS stimulation outcomes like nervousness or rapid heartbeat. Patients with existing renal or liver disease are noted to be at a greater risk for interaction-related adverse effects due to the potential for drug and metabolite accumulation.

Mechanism of Action

Melamine Mechanism of Action: Targets and Cascades

Melamine's toxicity involves three synergistic mechanistic domains, primarily targeting the renal tubules. First, it acts as a complex former by chemically binding with co-present metabolites, such as cyanuric acid, to create highly insoluble crystalline structures. The formation and aggregation of these precipitates cause physical obstruction and damage within the renal lumens, resulting in the development of acute tubular necrosis (ATN).

Second, the compound acts as an agonist on the Calcium-Sensing Receptor (CaSR) found on tubular cells. This specific molecular interaction causes a severe and sustained influx of intracellular calcium ( Ca^2+). This signaling over-activation triggers the apoptosis pathway, contributing to widespread cellular death. Third, the drug disrupts cellular redox balance by increasing oxidative stress. This effect further exacerbates cellular damage and mitochondrial dysfunction, contributing to the functional loss observed in the renal tissue.

Dosage and Administration Information

How Mepyramine Maleate is Used: Official Administration Guidelines

Official documents define the administration of Mepyramine Maleate (Pyrilamine) via oral routes, including solutions, syrups, and caplets, as well as topical preparations. The medicine is generally used for temporary relief of symptoms on an as-needed basis, with usage typically restricted to short-term application, often not to exceed seven days.

Oral administration is structured by precise intervals and dose limitations to maintain a standardized protocol. Immediate-release oral forms are typically taken every 4 to 8 hours as needed, while extended-release liquid formulations are administered every 12 hours. Caplets are directed to be taken with water. The key procedural constraint for all forms is the instruction not to exceed the recommended dosage specified by the labeling.

Standard Labeled Dosing Regimens

Population Single Dose (Examples) Maximum Daily Dose (Examples) Frequency Pattern
Adults (12+ years) 10 mL oral solution 40 mL oral solution Every 6 to 12 hours
Children (6 to 11 years) 5 mL oral solution 20 mL oral solution Every 6 to 12 hours

Official instructions mandate dose modification for age, explicitly setting lower dose and maximum limits for pediatric patients aged 6 to 11 years. Furthermore, administration of the liquid preparation requires the use of a calibrated device to ensure dose accuracy.

Recent Clinical Evidence

Research Evidence Overview

Research has explored Mepyramine (known generically as Melamine) in conditions associated with allergic symptoms and localized irritation. The evidence base focuses on clinical evaluation and findings reported in regulatory and scientific literature.


Evidence for Use in Allergic Rhinitis (Hay Fever)

Research exploring Mepyramine in conditions associated with allergic rhinitis has involved Randomized Controlled Trials (RCTs) and systematic reviews of the broader first-generation antihistamine class. These studies examined outcomes reflecting daily functioning and measured changes in symptom scores for sneezing, runny nose, and ocular itching. Findings describe patterns observed in patient populations with allergic rhinitis, a condition involving periods of heightened symptoms. The evidence level is generally described as Moderate by scientific reviews, as most high-level data aggregates across the entire class, and data focusing exclusively on Mepyramine in large-scale modern RCTs are limited.


Evidence for Use in Urticaria and Histamine-Related Itching

The evidence base for conditions associated with urticaria (hives) includes double-blind, placebo-controlled trials and systematic reviews. These studies examined outcomes related to intense pruritus (itching) and tracked changes in the Urticaria Activity Score (UAS). Research so far indicates that the H1-antihistamine class was observed in studies to show patterns of change in measured outcomes compared to placebo. The evidence level for this indication is generally described as High by scientific reviews, reflecting the established body of data for the H1-antihistamine class in this context.


Evidence for Localized Skin Irritation (Topical Formulations)

Research has studied the topical formulations in contexts involving localized pruritus, such as those associated with insect bites. Studies examined outcomes related to physical discomfort, including measuring pruritus intensity and suppression of histamine-induced wheal response. The evidence level is generally described as Moderate by scientific reviews. Comparative evidence is lacking for many acute reactions, and available data for long-term outcomes of topical use are not fully established.


Evidence Gaps and Areas of Research Uncertainty

The research landscape highlights several areas where certainty remains low. Comparative evidence specifically pitting Mepyramine against the newest generation of antihistamines is lacking in current systematic reviews. Data for certain special populations, such as specific comorbid groups, are limited or still emerging. The focus of the research has been on short-term symptom changes, meaning long-term effects are not fully established across the available literature.

Key Studies & References

  1. MIDOL COMPLETE- acetaminophen, caffeine, and pyrilamine maleate tablet - DailyMed
  2. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
  3. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria
  4. BSACI guideline for the management of chronic urticaria and angioedema (includes use of antihistamines in children and pregnancy/lactation)

Frequently Asked Questions (FAQ)

Common questions about Melamine (FAQ)

Q: Are there any long-term health concerns associated with using Melamine?

A: Research evidence indicates that long-term effects of Mepyramine (Melamine) are not fully established. Because of this evidence gap, official product information often focuses on short-term use. For topical (cream) formulations, regulatory documents specifically note that application for periods longer than a few days is not recommended.

Q: Why does Melamine interact with certain foods or drinks?

A: Interactions with substances like alcohol and certain medicines are due to an officially documented risk of additive CNS depression. This means the combination can enhance effects such as drowsiness and dizziness. Official labeling states the medicine should not be used with alcohol.

Q: Is it common to have stomach upset when first starting Melamine?

A: Official safety information cites Gastrointestinal Disorders as documented adverse reactions associated with the medicine. These issues include symptoms such as nausea and constipation. These effects are recognized in the drug's safety profile as documented adverse reactions.

Q: Does Melamine affect fertility?

A: Regulatory documentation for this class of medicine notes that long-term studies to determine the potential for impairment of fertility in animal models have not been performed. The lack of available long-term studies means the potential impact on fertility remains undefined in the regulatory literature.

Q: What is the official recommended use period for Melamine?

A: Official documents generally describe the use of the medicine as restricted to short-term application for temporary symptom relief. Official administration guidelines often direct use not to exceed seven days for oral preparations.

Q: How does Melamine compare to placebo in research studies?

A: Research studies have indicated patterns of change in measured allergic symptom outcomes in patient populations using the antihistamine class when compared against a placebo. Clinical trials for conditions like urticaria and hay fever examine outcomes such as reduced itching and sneezing scores.

Q: Is Melamine the same kind of medication as other similar drugs?

A: Mepyramine (Melamine) is officially classified as a first-generation antihistamine and an H1 receptor antagonist. This designation is a key differentiating factor, particularly because its structure allows it to easily cross the blood-brain barrier, which contributes to its sedating effect.

Q: Can Melamine be used by children?

A: Use in children aged 6 to under 12 years is permitted under specific dose limits, according to official labeling. Use in children under 6 years requires mandatory medical consultation, as official labeling notes children may be more sensitive to the drug’s effects.

Q: Is there any research about Melamine use during pregnancy?

A: Official regulatory labeling mandates that a health professional must be consulted before use if pregnant or breastfeeding. Some regulatory documents note that adequate and well-controlled studies in pregnant women are not available, which restricts the evidence base.

Q: Do studies suggest that Melamine is effective for its main purpose?

A: Research exploring the medicine for allergic rhinitis is described as having Moderate evidence, while for urticaria and histamine-related itching, the evidence level is generally described as High by scientific reviews. These levels reflect the body of data available for the H1-antihistamine class in these contexts.

Q: Does taking Melamine affect my ability to drive or operate machinery?

A: Official labeling advises using caution when driving a motor vehicle or operating heavy machinery. This warning is included because drowsiness and sedation are common side effects that can affect coordination and reaction time.

Q: Is Melamine a controlled substance?

A: The active ingredient in this medicine is not classified in a manner consistent with controlled substance scheduling in regulatory documents. This classification is consistent with the substance not being scheduled for abuse or dependence potential in regulatory documents.

Q: How is Melamine different from an antibiotic?

A: Mepyramine is officially classified as a first-generation antihistamine and H1 receptor antagonist. Its purpose is to counteract the effects of histamine in the body, which is pharmacologically distinct from the function of antibiotics, which are used to fight bacterial infections.

Q: Does Melamine cause tiredness or insomnia?

A: Official documentation lists drowsiness and sedation as common side effects of Mepyramine, which accounts for feelings of tiredness. Additionally, a rare occurrence of sleeplessness (insomnia) is also cited in safety warnings.

Q: What are the main findings from the clinical trials of Melamine?

A: Clinical trial findings typically examine measured outcomes reflecting daily functioning and symptom severity. This includes monitoring changes in symptom scores for sneezing, runny nose, and ocular itching, as well as changes in the Urticaria Activity Score (UAS).

Q: Is Melamine known to cause any skin reactions or rashes?

A: Official safety information documents the potential for skin and subcutaneous tissue reactions. These include skin sensitisation and local hypersensitivity reactions. The occurrence of a rash is also listed in safety warnings as a signal to stop use.

Q: What should I know about Melamine and alcohol consumption?

A: Official labeling advises against co-use with alcohol. This is due to the risk of enhanced and potentially severe Central Nervous System (CNS) depressant effects, which significantly increases drowsiness, confusion, and impaired judgment.

Q: Are there any rare but serious side effects linked to Melamine?

A: While rare, serious adverse events documented in official regulatory sources include convulsions (seizures), hyperpyrexia (very high fever), coma, and cardiorespiratory collapse. These effects are typically associated with overdose or overexposure.

Q: Is there a known antidote for Melamine overdose?

A: In case of an overdose, regulatory labeling directs patients to immediately seek medical help or contact a Poison Control Center. These instructions are the standard procedure for managing acute overexposure.

Q: Does Melamine interact with herbal remedies like St. John's Wort?

A: The medicine carries a potential for metabolic alteration risk with certain substances. The official labeling advises consulting a doctor or pharmacist about co-use with herbal remedies or supplements, as these may change how the drug is processed by the body.

Q: Is it true that Melamine is not suitable for people with certain heart conditions?

A: Official regulatory labeling mandates that a doctor must be consulted prior to use by patients with certain pre-existing conditions, including heart disease or high blood pressure. This caution is related to the known profile of first-generation antihistamines.

Q: What does the research say about Melamine's potential for abuse or dependence?

A: The active ingredient is not classified in a manner consistent with controlled substance scheduling in regulatory documents. This classification is used by authorities to assess a substance's potential for abuse or dependence.

Q: Is Melamine known to affect mood or cause psychological side effects?

A: Adverse reactions involving the Nervous System are documented and include effects such as confusion, excitement, and tremor. Rare reports of serious mental mood changes and hallucinations are also cited in official safety information.

How should Melamine be stored and disposed of?

Storage and Disposal Requirements for Mepyramine Maleate (Pyrilamine)

Official regulatory documents define specific conditions for storing and disposing of Mepyramine Maleate, the pharmaceutical compound referenced as Melamine. All forms must be stored out of the sight and reach of children.

Preparation Temperature and Environment Container and Integrity
Oral (Tablet) Store at controlled room temperature, 25 C (77 F), avoiding excessive heat above 40 C (104 F). Do not use if the package or blister unit is broken.
Topical (Cream) Store below 30 C, protected from light, and in a dry place. Store in the original container (e.g., tube).

Official disposal instructions prohibit discarding unused or expired medicine in wastewater or household waste. The proper procedure requires asking a pharmacist for guidance on disposing of pharmaceutical products you no longer use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Melamine found in:

A-Z Index: